Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- UPST +27%, MCY +22.8%, CFLT +13.8% (also announces strategic partnership with jio platforms), SMCI +10.1% (also delays 10-Q filing; in late 2024, received subpoenas from DOJ and SEC; also $700 mln private placement of convertible notes), CVS +9.8%, IVT +9.4%, PBI +8.7% (also names new CFO), UFCS +8.2%, RDWR +7.4%, MLYS +7.1%, FRSH +6.9%, ELMD +6.2%, DASH +6.1%, LAD +6.1%, TMHC +5.8%, MIR +5.1%, HIW +5%, PAX +4.7%, ANGI +4.6%, EW +4.5%, GILD +4.4% (also increases dividend), CAMT +4.1%, IAC +3.9%, BHF +3.7%, QSR +3.6%, AKR +3.5% (also increases dividend), CRSP +3.4%, GNRC +3.4%, HIVE +3.3%, ALKS +3.2%, HCSG +3.1%, BAM +3%, CHEF +2.9%, SPTN +2.9%, BVN +2.7%, RRR +2.1%, CME +2%, THC +1.9%, MRC +1.8%, COOP +1.7%, ST +1.6%, ECG +1.4%, DENN +1.3%, PAL +1.2%, GOLD +1.2%, ADC +1%, NI +1%,
Other news:
- ANAB +37.4% (to announce phase 2b trial data of Rosnilimab)
- RDFN +5.4% (announces content license agreement and partnership agreement with Zillow)
- SWTX +3.4% (confirms that the FDA has approved GOMEKLI for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas)
- VLN +2.9% (authorizes new $15 mln share repurchase program)
- MXCT +2.9% (enters strategic platform license with TG Therapeutics) HP +2.7% (CEO and a Director bought 57,356 shares worth nearly $1.6 mln)
- LTBR +2.6% (announces a significant milestone in its innovative nuclear fuel development efforts)
- RDDT +2.4% (ICE and RDDT announce data analytics partnership)
- POET +1.8% (provides business update)
- WAFD +1.6% (increases dividend)
- CPA +1.1% (reports Jan traffic)